Ipsen SA IPN

Aggregated presentation by day and by market Weekly report on share repurchases from 21st September to 22nd September 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1121/09/2026FR001025915021 158146,4614XPARIPSEN549300M6SGDPB4Z94P1121/09/2026FR00102591507 870146,0726CEUXIPSEN549300M6SGDPB4Z94P1121/09/2026FR00

Ipsen (ENXTPA:IPN) has refreshed its governance, with the board appointing Mariette Finet as Director and member of the Board Portfolio Committee following Michèle Ollier’s resignation earlier in the summer. Ipsen’s share price has softened in the short term, with a 1-month share price return down 10.18% and a 7-day move lower by 4.30%. The stock is still up 28.42% year to date and has delivered a 35.14% total shareholder return over the past year, suggesting longer term momentum remains...

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

Aggregated presentation by day and by market Weekly report on share repurchases from 14th September to 18th September 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1114/09/2026FR001025915000-IPSEN549300M6SGDPB4Z94P1115/09/2026FR001025915000-IPSEN549300M6SGDPB4Z94P1116/09/2026FR001025915000-IPSEN549300M6SGDPB

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

Ipsen appoints Mariette Finet to its Board of Directors PARIS, FRANCE, 18 SEPTEMBER 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Mariette Finet as a Director to its Board of Directors, effective immediately. Ms. Finet succeeds Ms. Michèle Ollier, who resigned from her position as Director on 1 August 2026. A Doctor of Medicine and graduate of the University of Nancy, Ms. Finet brings more than 35 years of experience across the healthcare, pharmaceutical and life sc

Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.

Aggregated presentation by day and by market Weekly report on share repurchases from 31st August to 04th September 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1131/08/2026FR00102591508 081162,4041XPARIPSEN549300M6SGDPB4Z94P1131/08/2026FR00102591501 919163,6365CEUXIPSEN549300M6SGDPB4Z94P1101/09/2026FR001025

Aggregated presentation by day and by market Weekly report on share repurchases from 7th September to 11th September 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1107/09/2026FR00102591501 587164,3678XPARIPSEN549300M6SGDPB4Z94P1107/09/2026FR0010259150 498164,4426CEUXIPSEN549300M6SGDPB4Z94P1108/09/2026FR00102

Ipsen stock has more than doubled over the past five years, yet the latest valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate points to material upside, while market multiples and the broader scorecard suggest the shares are not straightforwardly cheap. Ipsen has returned 108.7% over five years, which puts extra focus on whether today’s price still offers a margin of safety. The completed acquisition of Kartos Therapeutics may support longer term...

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

Aggregated presentation by day and by market Weekly report on share repurchases on 11th August 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1111/08/2026FR00102591507 185155,8901XPARIPSEN549300M6SGDPB4Z94P1111/08/2026FR0010259150 900156,4042TQEXIPSEN549300M6SGDPB4Z94P1111/08/2026FR00102591501 459156,3524CEUX

As the global neurotoxin market expands across cosmetic facial aesthetics and neurological therapeutic applications, Dysport (abobotulinumtoxinA)—developed and commercialized by Ipsen and Galderma—continues to maintain a critical market share alongside Botox (AbbVie/Allergan), Xeomin (Merz Aesthetics), Jeuveau (Evolus), and long-acting entry Daxxify (Revance Therapeutics).Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The "DYSPORT Sales Forecast and Market Size Analysis - 2034" has been added to Rese

Aggregated presentation by day and by market Weekly report on share repurchases from 04th August to 05th August 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1104/08/2026FR001025915010 250156,7509XPARIPSEN549300M6SGDPB4Z94P1105/08/2026FR00102591504 383158,0699XPARIPSEN549300M6SGDPB4Z94P1105/08/2026FR00102591

Exelixis Inc (EXEL) reports robust Q2 2026 results with $629M in revenues, while navigating slower NET adoption and advancing its zanzalintinib pipeline toward key regulatory milestones.

Aggregated presentation by day and by market Weekly report on share repurchases from 27th July to 31st July 2026 Name of the IssuerIdentify code of the IssuerTransaction dayIdentify code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1127/07/2026FR00102591509 022159,0397XPARIPSEN549300M6SGDPB4Z94P1128/07/2026FR00102591503 091158,6554XPARIPSEN549300M6SGDPB4Z94P1131/07/2026FR0010259150 20